Download PDF
Pharmacopsychiatry 2000; 33(2): 54-59
DOI: 10.1055/s-2000-7971
Original Paper
Georg Thieme Verlag Stuttgart ·New York

Influence of Methodology on Outcomes of Randomised Clozapine Trials

K. Wahlbeck1 , A. Tuunainen1 , S. Gilbody2 , C. E. Adams3
  • 1Department of Psychiatry, University of Helsinki, Helsinki, Finland
  • 2NHS Centre for Reviews and Dissemination, University of York, York, U.K.
  • 3Cochrane Schizophrenia Group, Oxford, U.K.
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

The aim of this study was to clarify the impact of various methodological quality factors on reported outcome of randomised clozapine trials. Trials comparing the atypical antipsychotic clozapine with other antipsychotic drugs were identified in extensive electronic searches. Two independent reviewers extracted data on methodology and primary outcomes, and assessed trial quality by use of three sets of criteria (Cochrane, Delphi, and Jadad). There was no association between trial quality, as measured by any of the criteria sets, and primary measures of outcome. Trials with the best score for randomisation and concealment according to the Delphi scale had a significantly lower relative risk for relapse in clozapine-treated groups, and studies with well reported random order generation according to Jadad criteria tended to have better odds ratios for clinical improvement on clozapine. These findings strengthen the evidence of true clozapine superiority in these aspects. No other quality items correlated to the primary outcomes. Inadequate randomisation techniques may be a source of bias in clozapine studies, but much more research is needed on the connections between trial quality and trial outcome.

References

  • 1 Stern R G, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia.  Biol. Psychiatry.. 1997;  42 -143
    PubMedGoogle Scholar
  • 2 Johnson T. Clinical trials in psychiatry: background and statistical perspective.  Stat. Meth. Med. Res.. 1998;  7 209-234
    PubMedGoogle Scholar
  • 3 Moher D, Pham B, Jones A, Cook D J, Jadad A R, Moher M. et al . Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?.  Lancet. 1998;  352 -613
    PubMedGoogle Scholar
  • 4 Chalmers T C, Celano P, Sacks H S, Smith H. Bias in treatment assignment in controlled clinical trials.  N. Engl. J. Med.. 1983;  309 1358-1361
    PubMedGoogle Scholar
  • 5 Schulz K F, Chalmers I, Hayes R J, Altman D. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials.  JAMA. 1995;  273 408-412
    CrossrefPubMedGoogle Scholar
  • 6 Baldessarini R J, Frankenburg F R. Clozapine: A novel antipsychotic agent.  N. Engl. J. Med.. 1991;  324 746-754
    PubMedGoogle Scholar
  • 7 Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.  Am. J. Psychiatry.. 1999;  156 990-999
    PubMedGoogle Scholar
  • 8 Moher D, Jadad A R, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomised controlled trials: an annotated bibliography of scales and checklists.  Contr. Clin. Trials.. 1995;  16 62-73
    PubMedGoogle Scholar
  • 9 Wahlbeck K, Cheine M, Essali M A. Clozapine versus typical neuroleptic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software 1999
    Google Scholar
  • 10 Tuunainen A, Gilbody S M. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software 1999
    Google Scholar
  • 11 Mulrow C D, Oxman A D. eds .Cochrane Collaboration Handbook [updated September 1997]. In: The Cochrane Library, Issue 1. Oxford: Update Software 1998
    Google Scholar
  • 12 Verhagen A P, de Vet H CW, de Bie R A, Kessels A GH, Boers M, Bouter L M. et al . The Delphi list; a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus.  J. Clin. Epid.. 1998;  51 1235-1241
    PubMedGoogle Scholar
  • 13 Jadad A R, Moore R A, Carroll D, Jenkinson C, Reynolds D JM, Gavaghan D J. et al . Assessing the quality of reports of randomized clinical trials: is blinding necessary?.  Contr. Clin. Trials. 1996;  17 1-12
    CrossrefPubMedGoogle Scholar
  • 14 Overall J E, Gorham D R. The brief psychiatric rating scale.  Psychol. Rep.. 1962;  10 799-812
    CrossrefPubMedGoogle Scholar
  • 15 Review Manager 3.1  (computer program). Oxford, UK: Update Software 1998
  • 16 Leon C A, Estrada H. Efectos terapeuticos de la Clozapina sobre los sintomas de Psicosis.  Rev. Colomb. Psiquiatria. 1974;  3 309-318
    PubMedGoogle Scholar
  • 17 Gerlach J, Koppelhus P, Helweg E, Monrad A. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.  Acta Psych. Scand.. 1974;  50 410-424
    PubMedGoogle Scholar
  • 18 Fischer-Cornelssen K, Ferner U, Steiner H. Multifokale Psychopharmakaprüfung („Multihospital Trial”).  Arzneimittelforschung. 1974;  24 1706-1724
    PubMedGoogle Scholar
  • 19 Singer K, Law S. Comparative double-blind study with clozapine (Leponex) and chlorpromazine in acute schizophrenia.  J. Int. Med. Res.. 1974;  2 433-435
    PubMedGoogle Scholar
  • 20 Gerlach J, Thorsen K, Fog R. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.  Psychopharmacologia.. 1975;  40 341-350
    PubMedGoogle Scholar
  • 21 Chiu E, Burrows G, Stevenson J. Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness.  Aust. N. Z. J. Psychiatry.. 1976;  10 343-347
    PubMedGoogle Scholar
  • 22 Fischer-Cornelssen K A, Ferner U J. An example of European multicenter trials: multispectral analysis of clozapine.  Psychopharmacology Bull.. 1976;  12 34-39
    PubMedGoogle Scholar
  • 23 Ciurezu T, Lonescu R, Nica-Udangiu S, Niturad D, Oproiu L, Tudorache D. et al . Étude clinique en “double-blind” du HF 1854 (= LX 100 - 129 = clozapine = Leponex) comparé à l'halopéridol.  Neurol. Psychiatr. (Bucur). 1976;  14 29-34
    PubMedGoogle Scholar
  • 24 Guirguis E, Voineskos G, Gray J, Schlieman E. Clozapine (Leponex) vs Chlorpromazine (Largactil) in acute schizophrenia (a double-blind controlled study).  Curr. Ther. Res.. 1977;  21 707-719
    PubMedGoogle Scholar
  • 25 Itoh H, Miura S, Yagi G, Sakurai S, Ohtsuka N. Some methodological considerations for the clinical evaluation of neuroleptics - comparative effects of clozapine and haloperidol on schizophrenics.  Folia Psychiatr. Neurol. Jpn.. 1977;  31 17-24
    PubMedGoogle Scholar
  • 26 Erlandsen C. Utprøving av et nytt nevroleptikum, Leponex (clozapin) hos schizofrene med lang sykehistorie.  Nord. J. Psychiatry.. 1981;  35 248-253
    PubMedGoogle Scholar
  • 27 Shopsin B, Klein H, Aaronsom M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison.  Arch. Gen. Psychiatry.. 1979;  36 657-664
    PubMedGoogle Scholar
  • 28 Gelenberg A J, Doller J C. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study.  J. Clin. Psychiatry.. 1979;  40 238-240
    PubMedGoogle Scholar
  • 29 Honigfeld G, Patin J, Singer J. Clozapine antipsychotic activity in treatment-resistant schizophrenics.  Adv. Ther.. 1984;  1 77-97
    PubMedGoogle Scholar
  • 30 Xu W R, Bao-long Z, Quo C, Mei-fang G. A double-blind study of clozapine and chlorpromazine treatment in the schizophrenics.   Chin. J. Nerv. Mental Dis.. 1985;  11 222-224
    PubMedGoogle Scholar
  • 31 Claghorn J, Honigfeld G, Abuzzahab F S Sr, Wang R, Steinbook R, Tuason V. et al . The risks and benefits of clozapine versus chlorpromazine.  J. Clin. Psychopharmacology.. 1987;  7 377-384
    PubMedGoogle Scholar
  • 32 Kane J M, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group . Clozapine for the treatment of treatment-resistant schizophrenia: a double blind comparison with chlorpromazine.  Arch. Gen. Psychiatry.. 1988;  45 789-796
    PubMedGoogle Scholar
  • 33 Potter W Z, Ko G N, Zhang L D, Yan W. Clozapine in China: a review and preview of US/PRC collaboration.  Psychopharmacology.. 1989;  99 -91
    PubMedGoogle Scholar
  • 34 Klieser E, Schönell H. Klinisch-pharmakologische Studien zur Behandlung schizophrener Minussymptomatik.  In Möller HJ, Pelzer E, editors. Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Berlin: Springer-Verlag 1990
    Google Scholar
  • 35 Liu B L, Chen Y Y, Yang D S. et al . Effects of thioridazine on schizophrenics and clinical utility of plasma levels.  Chin. J. Neurol. Psychiatry.. 1994;  27 364-367
    PubMedGoogle Scholar
  • 36 Klieser W, Strauss W H, Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia.  Acta Psych. Scand.. 1994;  89 Suppl. 380 68-73
    PubMedGoogle Scholar
  • 37 Lee M A, Jayathilake K, Meltzer H Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.  Schizophrenia Res.. 1999;  37 1-11
    PubMedGoogle Scholar
  • 38 Tamminga C A, Thaker G K, Moran M, Kakigi T, Gao X M. Clozapine in tardive dyskinesia: observations from human and animal model studies.  J. Clin. Psychiatry.. 1994;  55 Suppl. B 102-106
    PubMedGoogle Scholar
  • 39 Klieser E, Lehmann E, Heinrich K. Risperidone in comparison with various treatments of schizophrenia. In Kane JM, Möller HJ, Awouters F, editors. Medical Psychiatry Vol. 3. Serotonin in antipsychotic treatment: Mechanisms and clinical practice. New York: Marcel Dekker 1996
    Google Scholar
  • 40 Kane J M, Schooler N R, Marder S, Wirshing W, Ames D, Umbricht D. et al . Efficacy of clozapine versus haloperidol in a long-term clinical trial [Abstract].  Schizophrenia Res.. 1996;  18 127
    PubMedGoogle Scholar
  • 41 Essock S M, Hargreaves W A, Covell N H, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.  Psychopharmacology Bull.. 1996;  32 683-697
    PubMedGoogle Scholar
  • 42 Kumra S, Frazier J A, Jacobsen L K, McKenna K, Gordon C T, Lenane M C. et al . Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison.  Arch. Gen. Psychiatry.. 1996;  53 1090-1097
    PubMedGoogle Scholar
  • 43 Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L. et al . A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia.  N. Engl. J. Med.. 1997;  337 -815
    PubMedGoogle Scholar
  • 44 Hong C J, Chen J Y, Chiu H J, Sim C B. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia.  Int. Clin. Psychopharmacology.. 1997;  12 123-130
    PubMedGoogle Scholar
  • 45 Buchanan R W, Breier A, Kirkpatrick B, Ball P, Carpenter W T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.  Am. J. Psychiatry.. 1998;  155 751-760
    PubMedGoogle Scholar
  • 46 Bondolfi G, Dufour H, Patris M, May J P, Billeter U, Eap C B. et al . Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study.  Am. J. Psychiatry.. 1998;  155 499-504
    PubMedGoogle Scholar
  • 47 Beuzen J N, Birkett M A, Kiesler G M, Wood A J. Olanzapine vs. clozapine: a double-blind international study in the treatment of resistant schizophrenic patients. Presented at the 21 st Collegium Internationale Neuro-Psychopharmacologicum Congress, Glasgow, United Kingdom. 1998 July 12 - 16
    Google Scholar
  • 48 Howanitz E, Pardo M, Smelson D A, Engelhart C, Eisenstein N, Losonczy M F. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia.  J. Clin. Psychiatry.. 1999;  60 41-44
    PubMedGoogle Scholar
  • 49 Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years.  BMJ. 1998;  317 1181-1184
    PubMedGoogle Scholar

PhD MD, Kristian Wahlbeck,

Department of Psychiatry University of Helsinki

Lappviksvägen

PB 320

FIN-00029 HUCH

Finland

Email: Kristian.Wahlbeck@Helsinki.Fi

      >